Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

238
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
238
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

550
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
550
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

27
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
27
Ovarian Cycle01:27

Ovarian Cycle

1.5K
The menstrual cycle includes a critical component known as the ovarian cycle, which undergoes two main phases each month—the follicular phase and the luteal phase. The follicular phase is variable and averaging around 14 days. Ovulation, triggered by a surge in luteinizing hormone (LH), marks the transition between the two phases. The second phase, the luteal phase, is relatively consistent, lasting approximately 14 days, and is marked by the activity of the corpus luteum. While a cycle...
1.5K
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

552
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
552
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

576
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
576

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes with cerclage for short cervix ≤20.9mm before 24 weeks in singletons without prior preterm birth: a focused meta-analysis of randomized controlled trials.

American journal of obstetrics & gynecology MFM·2026
Same author

Impact of Maternal COVID-19 Infection Versus Vaccination on Mucosal Immunity in Breastmilk.

Journal of clinical medicine·2026
Same author

Amniocentesis prior to cerclage: practice patterns and obstetric outcomes.

American journal of obstetrics & gynecology MFM·2026
Same author

Risk factors and mortality in infants who received bag and mask ventilation at birth: a secondary analysis from the global network maternal newborn health registry.

Journal of perinatology : official journal of the California Perinatal Association·2026
Same author

Utility of Methadone:Metabolite Ratio as Marker of Methadone Metabolism During Methadone Initiation in Pregnancy.

Journal of addiction medicine·2026
Same author

Rebalancing prostanoids: How differential COX-1 and COX-2 inhibition explains the success and limitations of low-dose aspirin in pregnancy.

Seminars in perinatology·2026

Related Experiment Video

Updated: Aug 9, 2025

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

1.7K

Obstetric Indications for Progestin Therapy.

Rupsa C Boelig1

  • 1Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, Sidney Kimmel Medical College, Thomas Jefferson University, 833 Chestnut Street, Level 1, Philadelphia, PA 19107, USA; Department of Clinical Pharmacology and Therapeutics, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA, USA.

Obstetrics and Gynecology Clinics of North America
|February 23, 2023
PubMed
Summary
This summary is machine-generated.

Vaginal progesterone effectively reduces preterm birth risk in high-risk singleton pregnancies. It may also lower recurrent preterm birth and improve live birth rates in women with prior miscarriages or early bleeding.

Keywords:
17-OHPC17-hydroxyprogesterone caproatePreterm birthProgesteroneProgestin

More Related Videos

Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy
03:30

Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy

Published on: October 25, 2024

1.6K
Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

16.7K

Related Experiment Videos

Last Updated: Aug 9, 2025

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model
06:49

Methods for Studying Uterine Contributions to Pregnancy Establishment in an Ovariectomized Mouse Model

Published on: April 7, 2023

1.7K
Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy
03:30

Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy

Published on: October 25, 2024

1.6K
Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development
07:56

Contractility Measurements of Human Uterine Smooth Muscle to Aid Drug Development

Published on: January 26, 2018

16.7K

Area of Science:

  • Reproductive Medicine
  • Obstetrics
  • Perinatal Health

Background:

  • Preterm birth is a significant global health concern.
  • Identifying effective interventions for high-risk pregnancies is crucial.
  • Recurrent preterm birth and miscarriage impact live birth rates.

Purpose of the Study:

  • To evaluate the efficacy of vaginal progesterone in preventing preterm birth.
  • To assess the impact of 17-hydroxyprogesterone caproate (17-OHPC) on recurrent preterm birth.
  • To explore the benefits of vaginal progesterone in singleton pregnancies with a history of miscarriage or early bleeding.

Main Methods:

  • Meta-analyses of randomized controlled trials were conducted.
  • Data from selected high-risk singleton pregnancies were analyzed.
  • A specific trial investigated progesterone's effect on live birth rates in specific cohorts.

Main Results:

  • Meta-analyses confirm vaginal progesterone reduces preterm birth risk in high-risk singletons.
  • 17-OHPC shows potential in decreasing recurrent preterm birth.
  • Evidence suggests vaginal progesterone may improve live birth rates in certain pregnancy complications.

Conclusions:

  • Vaginal progesterone is a valuable tool for managing preterm birth risk in selected high-risk singleton pregnancies.
  • 17-OHPC offers a potential strategy for preventing recurrent preterm birth.
  • Further research may confirm progesterone's role in improving outcomes for pregnancies complicated by miscarriage or bleeding.